Quantum Genomics
PARIS, FR· latest recorded location
Quantum Genomics is named on 7 US grants and 8 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 7
- Published applications
- 8
- Inventors
- 14
- Granted in 2026 so far
- 0
- Most recent grant
- 31 May 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 1 | 2 |
| 2016 | 3 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 2 | 2 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
By publication year.
Technology areas
Share of 15 documents
Recent patents
- Compounds and compositions comprising the same for treating hypertension or heart failure31 May 2022US 11,345,658 B2
- Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same7 Dec 2021US 11,192,907 B2
- Combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent30 Mar 2021US 10,959,938 B2
- Crystalline phase of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine8 Nov 2016US 9,487,477 B2
- Method for the preparation of (3S,3S′) 4,4′-disulfanediylbis (3-aminobutane 1-sulfonic acid)17 May 2016US 9,340,497 B2
- Pharmaceutical combination comprising a brain aminopeptidase a inhibitor, a diuretic and a blocker of the systemic renin-angiotensin system27 Jul 2023US 2023/0233492 A1
- Compounds and compositions comprising the same for treating hypertension or heart failure10 Feb 2022US 2022/0041548 A1
- Novel aminophosphinic derivatives as aminopeptidase a inhibitors7 Oct 2021US 2021/0309677 A1
- Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same7 Oct 2021US 2021/0309678 A1
- Crystalline phase of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) with l-lysine4 Aug 2016US 2016/0221940 A1
Most cited
By later US patents